Kevin Moreau
Overview
Explore the profile of Kevin Moreau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
4941
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munns J, Beale A, Michaelides I, Peak-Chew S, Mihut A, Major-Styles C, et al.
Philos Trans R Soc Lond B Biol Sci
. 2025 Jan;
380(1918):20230342.
PMID: 39842482
The mammalian cryptochrome proteins (CRY1 and CRY2) are transcriptional repressors most notable for their role in circadian transcriptional feedback. Not all circadian rhythms depend on CRY proteins, however, and the...
2.
Ruffilli C, Roth S, Zelcer N, Moreau K
Sci Rep
. 2025 Jan;
15(1):504.
PMID: 39748066
Dysregulation of integral membrane proteins (IMPs) has been linked to a myriad of diseases, making these proteins an attractive target in drug research. Whilst PROTAC technology has had a significant...
3.
Ortiz Zacarias N, Roth S, Broekhuis J, van der Es D, Moreau K, Heitman L
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201670
CC chemokine receptor 2 (CCR2) has been linked to many inflammatory and immune diseases, making it a relevant drug target. Yet, all CCR2 antagonists developed so far have failed in...
4.
Bagal S, Astles P, Diene C, Argyrou A, Crafter C, Cassar D, et al.
J Med Chem
. 2024 Jul;
67(14):11732-11750.
PMID: 38991141
Androgen receptor (AR) signaling plays a key role in the progression of prostate cancer. This study describes the discovery and optimization of a novel series of AR PROTAC degraders that...
5.
Beauvais V, Moreau K, Zunar B, Hervouet-Coste N, Novacic A, Le Dantec A, et al.
RNA
. 2023 Nov;
30(1):89-98.
PMID: 37914399
The eukaryotic THO complex coordinates the assembly of so-called messenger RNA-ribonucleoprotein particles (mRNPs), a process that involves cotranscriptional coating of nascent mRNAs with proteins. Once formed, mRNPs undergo a quality...
6.
Horberg J, Hallback B, Moreau K, Reymer A
QRB Discov
. 2023 Aug;
3:e23.
PMID: 37529293
Selective DNA binding by transcription factors (TFs) is crucial for the correct regulation of DNA transcription. In healthy cells, promoters of active genes are hypomethylated. A single CpG methylation within...
7.
Horberg J, Moreau K, Reymer A
QRB Discov
. 2023 Aug;
3:e4.
PMID: 37529292
Changing torsional restraints on DNA is essential for the regulation of transcription. Torsional stress, introduced by RNA polymerase, can propagate along chromatin facilitating topological transitions and modulating the specific binding...
8.
Hemkens M, Stamp K, Loberg L, Moreau K, Hart T
Drug Discov Today
. 2023 May;
28(8):103643.
PMID: 37244567
Targeted protein degraders (TPDs), which act through the ubiquitin proteasome system (UPS), are one of the newest small-molecule drug modalities. Since the initiation of the first clinical trial in 2019,...
9.
Ruffilli C, Roth S, Rodrigo M, Boyd H, Zelcer N, Moreau K
ACS Pharmacol Transl Sci
. 2022 Oct;
5(10):849-858.
PMID: 36268122
Targeted protein degradation (TPD) is a promising therapeutic modality to modulate protein levels and its application promises to reduce the "undruggable" proteome. Among TPD strategies, Proteolysis TArgeting Chimera (PROTAC) technology...
10.
Trapotsi M, Mouchet E, Williams G, Monteverde T, Juhani K, Turkki R, et al.
ACS Chem Biol
. 2022 Jul;
17(7):1733-1744.
PMID: 35793809
PROteolysis TArgeting Chimeras (PROTACs) use the ubiquitin-proteasome system to degrade a protein of interest for therapeutic benefit. Advances made in targeted protein degradation technology have been remarkable, with several molecules...